, Volume 16, Issue 1, pp 46–87 | Cite as

Antineoplastic Drugs: Clinical Pharmacology and Therapeutic Use

  • Richard A. Bender
  • Leonard A. Zwelling
  • James H. Doroshow
  • Gershon Y. Locker
  • Kenneth R. Hande
  • Donald S. Murinson
  • Michael Cohen
  • Charles E. Myers
  • Bruce A. Chabner
Review Article


Methotrexate Clinical Pharmacology Bleomycin Adriamycin Cytarabine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adamson, I.Y. and Bowden, D.H.: The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. American Journal of Pathology 77: 185–197 (1974).PubMedGoogle Scholar
  2. Adamson, R.H.: Daunomycin and adriamycin: A hypothesis concerning antitumor activity and cardiotoxicity. Cancer Chemotherapy Reports 58(1): 293–294 (1974).Google Scholar
  3. Alberts, D.S. and van Daalen Wetters, T.: The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Research 36: 2785–2789 (1976a).PubMedGoogle Scholar
  4. Alberts, D.S. and van Daalen Wetters, T.: The effect of allopurinol on cyclophosphamide antitumor activity. Cancer Research 36: 2790–2794 (1976b).PubMedGoogle Scholar
  5. Allen, L.M. and Creaven, P.J.: Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. European Journal of Cancer 11: 697–707 (1975).PubMedGoogle Scholar
  6. Ambre, J.J. and Fischer, L.J.: The effect of prednisolone and other factors on the catabolism of 5-fluorouracil in rats. Journal of Laboratory and Clinical Medicine 78: 343–353 (1971).PubMedGoogle Scholar
  7. Ansfield, F.; Klotz, J.; Nealon, T. et al.: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. A preliminary report. Cancer 39: 34–40 (1977).PubMedGoogle Scholar
  8. Arcamone, F.; Bernardi, L.; Gardino, P. et al.: Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7-9-diepidaunorubicin, and their β anomers. Cancer Treatment Reports 60: 829–834 (1976).PubMedGoogle Scholar
  9. Arena, B.; D’Alessandro, N.; Dusonchet, L. et al.: Influence of pharmacokinetic variations on the pharmacologic properties of adriamycin; in Carter, DiMarco, Ghione et al. (Eds) International Symposium on Adriamycin, p.96–116 (Springer-Verlag, New York 1972).Google Scholar
  10. Arnold, H. and Bourseaux, F.: Synthese und Abbau cytostatisch wirksamer cyclischer N-phosphamidester des bis-(β-chlorathyl)-amins. Angew Chem (Engl) 70: 539–544 (1958).Google Scholar
  11. Bachur, N.R.; Reiter, W. and Arena, E.: Cardiac uptake of adriamycin (NSC-123127) not affected by stropanthin G (NSC-25485). Cancer Chemotherapy Reports 59: 765–766 (1975).Google Scholar
  12. Bachur, N.R.; Riggs, C.E.; Green, M.R. et al.: Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clinical Pharmacology and Therapeutics 21: 70–77 (1977).PubMedGoogle Scholar
  13. Bacigalupo, G.: Uncoupling the oxidative phosphorylation in the combined chemotherapy of cancer. Acta Unio International Journal of Cancer 20: 52–53 (1964).Google Scholar
  14. Bagley, C.M.; Bostick, F.W. and DeVita, V.T.: Clinical pharmacology of cyclophosphamide. Cancer Research 33: 226–233 (1973).PubMedGoogle Scholar
  15. Band, P.R.; Holland, J.F.; Bernard, J. et al.: Treatment of central nervous system leukemia with intrathecal cytosine arabinoside. Cancer 32: 744–748 (1973).PubMedGoogle Scholar
  16. Barlogie, B.; Drewinko, B.; Johnston, D.A. et al.: The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line. Cancer Research 36: 1975–1979 (1976).PubMedGoogle Scholar
  17. Bearden, J. Jr and Haidle, C.W.: Stimulation of bleomycin-induced fragmentation of DNA by intercalating agents. Biochemical and Biophysical Research Communications 65: 371–377 (1975).PubMedGoogle Scholar
  18. Beck, D.J. and Brubaker, R.R.: Effect of cis-platinum (II) diamminodichloride on wild type and deoxyribonucleic acid repair-deficient mutants of Escherichia coli. Journal of Bacteriology 116: 1247–1252 (1973).PubMedGoogle Scholar
  19. Beck, D.J. and Brubaker, R.R.: Mutagenic properties of cis-platinum (II) diamminodichloride in Escherichia coli. Mutation Research 27: 181–189 (1975).PubMedGoogle Scholar
  20. Bellet, R.E.; Mastrangelo, M.J.; Engstrom, P.F. et al.: Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study). Neoplasma 20: 303–309 (1973).PubMedGoogle Scholar
  21. Bender, R.A.; Bleyer, W.A.; Frisby, S.A. et al.: Alteration of methotrexate uptake in human leukemia cells by other agents. Cancer Research 35: 1305–1308 (1975).PubMedGoogle Scholar
  22. Bender, R.A.; Castle, M.C.; Margileth, D.A. et al.: The pharmacokinetics of [3H]-vincristine in man. Clinical Pharmacology and Therapeutics. 22: 430–438 (1977).PubMedGoogle Scholar
  23. Benjamin, R.S.: Clinical pharmacology of adriamycin (NSC-123127). Cancer Chemother. Rep. 6(3): 183–185 (1975a).Google Scholar
  24. Benjamin, R.S.: A practical approach to adriamycin (NSC-123127) toxicology. Cancer Chemotherapy Reports 6(3): 191–194 (1975b).Google Scholar
  25. Benjamin, R.S.; Riggs, C.E. and Bachur, N.R.: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 37: 1416–1420 (1977).PubMedGoogle Scholar
  26. Benjamin, R.S.; Wiernik, P.H. and Bachur, N.R.: Adriamycin chemotherapy — efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19–27 (1974).PubMedGoogle Scholar
  27. Bhattacharyya, B. and Wolff, J.: Maytansine binding to the vinblastine sites of tubulin. Federation of European Biochemical Societies Letters 75: 159–162 (1977).PubMedGoogle Scholar
  28. Bick, R.L.; Fekete, L.F. and Wilson, W.L.: Adriamycin and fibrinolysis. Thrombosis Research 8: 467–475 (1976).PubMedGoogle Scholar
  29. Birnie, G.D.; Kroeger, H. and Heidelberger, C.: Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2*-deoxyuridine and related compounds by nucleoside Phosphorylase. Biochemistry 2: 566–572 (1963).PubMedGoogle Scholar
  30. Bleyer, W.A.: Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treatment Reports. 61: 1419–1425 (1977).PubMedGoogle Scholar
  31. Bleyer, W.A. and Dedrick, R.L.: Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treatment Reports 61: 703–708 (1977).PubMedGoogle Scholar
  32. Bleyer, W.A.; Drake, J.C and Chabner, B.A.: Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. New England Journal of Medicine 289: 770–773 (1973).PubMedGoogle Scholar
  33. Bleyer, W.A.; Frisby, S.A. and Oliverio, V.T.: Uptake and binding of vincristine by murine leukemia cells. Biochemical Pharmacology 24: 633–639 (1975).PubMedGoogle Scholar
  34. Blum, R.H.; Carter, S.K. and Agre, K.: A clinical review of bleomycin: A new antineoplastic agent. Cancer 31: 903–913 (1973).PubMedGoogle Scholar
  35. Blum, R.H. and Dawson, D.M.: Vindesine (V)-Phase I study of a Vinca alkaloid. Proceedings of the American Association for Cancer Research 17: 108 (1976).Google Scholar
  36. Bodey, G.P.; Freireich, E.J.; Monto, R.W. et al.: Cytosine arabinoside (NSC 63878) therapy for acute leukemia in adults. Cancer Chemotherapy Reports 53: 59–66 (1969).Google Scholar
  37. Bonadonna, G.; Monfardini, S.; DeLena, M. et al.: Clinical trials with adriamycin. Results of three years study; in Carter; DiMarco; Ghione et al. (Eds) International Symposium on Adriamycin, p. 139–152 (Springer Verlag, New York 1972).Google Scholar
  38. Bourke, R.S.; West, C.R.; Chheda, G. et al.: Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Research 33: 1735–1746 (1973).PubMedGoogle Scholar
  39. Bristow, M.; Mason, J.; Billingham, M. et al.: Clinical evaluation of adriamycin cardiomyopathy. Proceedings of the American Society of Clinical Oncology 18: 334 (1977).Google Scholar
  40. Broughton, A. and Strong, J.E.: Radioimmunoassay of bleomycin. Cancer Research 36: 1418–1421 (1976).PubMedGoogle Scholar
  41. Bruckner, H.W. and Creasey, W.A.: The administration of 5-fluorouracil by mouth. Cancer 33: 14–18 (1974).PubMedGoogle Scholar
  42. Bruckner, H.W.; Schreiber, C. and Waxman, S.: Interaction of chemotherapeutic agents with methotrexate and 5-fluorouracil and its effect on de novo DNA synthesis. Cancer Research 35: 801–806 (1975).PubMedGoogle Scholar
  43. Buckner, C.D.; Rudolph, R.H.; Fefer, A. et al.: High-dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29: 357–365 (1972).Google Scholar
  44. Burgess, M.A.; Bodey, G.P.; Minow, R.A. et al.: Phase I-II evaluation of cyclocytidine. Cancer Treatment Reports 61: 437–443 (1977).PubMedGoogle Scholar
  45. Buroker, T.; Samson, M.; Correa, J. et al.: Hepatic artery infusion of 5-FUdR after prior systemic 5-fluorouracil. Cancer Treatment Reports 60: 1277–1279 (1976).PubMedGoogle Scholar
  46. Byfield, J.B.; Lee, Y.C. and Tu, L.: Molecular interactions between adriamycin and x-ray damage in mammalian tumor cells. International Journal of Cancer 19: 186–193 (1977).Google Scholar
  47. Capizzi, R.L.; Keiser, L.W. and Sartorelli, A.C.: Combination chemotherapy — theory and practice. Seminars in Oncology 4: 227–253 (1977).PubMedGoogle Scholar
  48. Carter, S.K.: Single and combination nonhormonal chemotherapy in breast cancer. Cancer 30: 1543–1555 (1972).PubMedGoogle Scholar
  49. Carter, S.K.: Adriamycin — A Review. Journal of the National Cancer Institute 55: 1265–1274 (1975).PubMedGoogle Scholar
  50. Carter, S.K. and Livingston, R.B.: Plant products in cancer chemotherapy. Cancer Treatment Reports 60: 1141–1156 (1976).PubMedGoogle Scholar
  51. Cassady, J.R.; Richter, M.P.; Piro, A.J. et al.: Radiation-adriamycin interactions: Preliminary clinical observations. Cancer 36: 946–949 (1975).PubMedGoogle Scholar
  52. Castle, M.C.; Margileth, D.A. and Oliverio, V.T.: Distribution and excretion of [3H]vincristine in the rat and the dog. Cancer Research 36: 3684–3689 (1976).PubMedGoogle Scholar
  53. Chabner, B.A.; Johns, D.G.; Coleman, C.N. et al.: Purification and properties of cytidine deaminase from normal and leukemic granulocytes. Journal of Clinical Investigation 53: 922–931 (1974).PubMedGoogle Scholar
  54. Chabner, B.A.; Levine, A.; Adamson, R. et al.: Initial clinical and pharmacological studies of Maytansine. Proceedings of the American Association for Cancer Research 18: 129 (1977).Google Scholar
  55. Chabner, B.A. and Young, R.C.: Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. Journal of Clinical Investigation 52: 1804–1811 (1973).PubMedGoogle Scholar
  56. Chang, P.; Wiernik, P.; Bachur, N. et al.: Failure to predict response of acute non-lymphocytic leukemia using assays for deoxycytidine kinase, cytidine deaminase, and daunomycin reductase. Proceedings of the American Society of Clinical Oncology 18: 352 (1977).Google Scholar
  57. Chary, K.K.; Higby, D.J.; Henderson, E.S. et al.: Phase I study of high-dose cis-dichlorodiammine platinum (II) with forced diuresis. Cancer Treatment Reports 61: 367–370 (1977).PubMedGoogle Scholar
  58. Chaudhuri, N.K.; Montag, B.J. and Heidelberger, C.: Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-14C and 5-fluorourotic acid-2-l4C in vivo. Cancer Research 18: 318–328 (1958).PubMedGoogle Scholar
  59. Chou, T.G; Hutchinson, D.J.; Schmid, F.A. et al.: Metabolism and selective effects of 1-β-D arabinofuranosylcytosine in L1210 and host tissue in vivo. Cancer Research 35: 225–236 (1975).PubMedGoogle Scholar
  60. Chu, M.Y.: Incorporation of arabinosyl cytosine into 27S ribonucleic acid and cell death. Biochemical Pharmacology 20: 2057–2064 (1971).PubMedGoogle Scholar
  61. Cihak, A.; Vesely, J. and Sorm, F.: Complete inhibition by 5-azacytidine of hormonal induction of tryptophan pyrrolase. Biochimica et Biophysica Acta 134: 486–489 (1967).Google Scholar
  62. Clarkson, B.; O’Connor, A.; Winston, L. et al.: The physiologic disposition of 5-fluorouracil and 5-fluoro-2’-deoxyuridine in man. Clin. Pharmacol. Thera. 5: 581–610 (1965).Google Scholar
  63. Clarkson, J.M. and Humphrey, R.M.: The effect of adriamycin on cell cycle progression and DNA replication in Chinese hamster ovary cells. Cancer Research 37: 200–205 (1977).PubMedGoogle Scholar
  64. Cohen, A.M.: The disposition of ftorafur in rats after intravenous administration. Drug Metabolism and Disposition 3: 303–308 (1975).PubMedGoogle Scholar
  65. Cohen, J.L.; Irwin, L.E.; Marshall, G.J. et al.: Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC-19893). Cancer Chemotherapy Reports 58: 723–731 (1974).Google Scholar
  66. Cohen, S.S.; Flaks, J.G.; Barner, H.D. et al.: The mode of action of 5-fluorouracil and its derivatives. Proceedings of the National Academy of Science U.S.A. 44: 1004–1012 (1958).Google Scholar
  67. Cooper, G.M.; Dunning, W.F. et al.: Role of catabolism in pyrimidine utilization for nucleic acid synthesis in vivo. Cancer Research 32: 390–397 (1972).PubMedGoogle Scholar
  68. Creasey, W.A.: Modifications in biochemical pathways produced by the Vinca alkaloids. Cancer Chemotherapy Reports 52: 501–507 (1968).Google Scholar
  69. Creasey, W.A. and Markiw, M.E.: Biochemical effects of the Vinca alkaloids. III. The synthesis of ribonucleic acid and the incorporation of amino acids in Ehrlich ascites cells in vitro. Biochimica et Biophysica Acta 103: 635–645 (1965).PubMedGoogle Scholar
  70. Creasey, W.A.; Mcintosh, L.S.; Brescia, T. et al.: Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Research 36: 216–221 (1976).PubMedGoogle Scholar
  71. Creasey, W.A.; Scott, A.I.; Wei, C.G. et al.: Pharmacologic studies with vinblastine in the dog. Cancer Research 35: 1116–1120 (1975).PubMedGoogle Scholar
  72. Creaven, P.J. and Allen, L.M.: EPEG, a new antineoplastic epipodophyllotoxin. Clinical Pharmacology and Therapeutics 18: 221–226 (1975a).PubMedGoogle Scholar
  73. Creaven, P.J. and Allen, L.M.: PTG, a new antineoplastic epipodophyllotoxin. Clinical Pharmacology and Therapeutics 18: 227–232 (1975b).PubMedGoogle Scholar
  74. Creaven, P.J.; Newman, S.J.; Selawry, O.S. et al.: Clinical trial of weekly administration of 4’-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside (NSC-141540; VP-16-213). Cancer Chemother. Rep. 58: 901–907 (1974).PubMedGoogle Scholar
  75. Curreri, A.R.; Ansfield, F.J.; McIver, F.A. et al.: Clinical studies with 5-fluorouracil. Cancer Research 18: 478–484 (1958).PubMedGoogle Scholar
  76. DeConti, R.C.; Toftness, B.R.; Lange, R.C. et al.: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Research 33: 1310–1315 (1973).PubMedGoogle Scholar
  77. DeFronzo, R.A.; Braine, H.; Colvin, M.O. et al.: Water intoxication in man after cyclophosphamide therapy: Time course and relation to drug activation. Annals of Internal Medicine 78: 861–869 (1973).PubMedGoogle Scholar
  78. Dentino, M.E.; Yum, M.N.; Rohn, R.J. et al.: The long-term effect of cis-platinum diamminedichloride on renal function in man. Proceedings of the American Association for Cancer Research 18: 116 (1977).Google Scholar
  79. DiMarco, A.: Adriamycin (NSC-123127): Mode and mechanism of action. Cancer Chemotherapy Reports 6(3): 91–106 (1975).Google Scholar
  80. DiMarco, A.; Casazza, A.M.; Gambetta, R. et al.: Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives. Cancer Research 36: 1962–1966 (1976).Google Scholar
  81. Dixon, R.L.: Effect of chloramphenicol on the metabolism and lethality of cyclophosphamide in rats. Proceedings of the Soc. Experi. Bio. Med. 127: 1151–1155 (1968).Google Scholar
  82. Dixon, R.L.; Henderson, E.S. and Rail, D.P.: Plasma protein binding of methotrexate and its displacement by various drugs. Federation Proceedings 24: 454 (1965).Google Scholar
  83. Drake, J.C.; Stoller, R.G. and Chabner, B.A.: Characterization of the enzyme uridine-cytidine kinase isolated from a cultured human cell line. Biochemical Pharmacology 26: 64–66 (1977).PubMedGoogle Scholar
  84. Drewinko, B.; Brown, B.W. and Gottlieb, J.A.: The effect of cisdiamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Research 33: 3091–3095 (1973).PubMedGoogle Scholar
  85. Duncan, J.H.; Colvin, M.O. and Fenselau, C.: Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicology and Applied Pharmacology 24: 317–323 (1973).PubMedGoogle Scholar
  86. Ellison, R.R.; Holland, J.F.; Weil, M. et al.: Arabinosylcytosine: a useful agent in the treatment of acute leukemia in adults. Blood 32: 507–523 (1968).PubMedGoogle Scholar
  87. Ensminger, W.D. and Frei, E.: The prevention of methotrexate toxicity by thymidine infusion in humans. Cancer Research 37: 1857–1863 (1977).PubMedGoogle Scholar
  88. EORTC: Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumors. British Medical Journal 2: 744–748 (1972).Google Scholar
  89. EORTC: Epipodophyllotoxin VP 16213 in treatment of acute leukemias, haematosarcomas, and solid tumors. British Medical Journal 3: 199–202 (1973).Google Scholar
  90. Etcubanas, E. and Wilbur, J.R.: Uncommon side effects of adriamycin. Cancer Chemotherapy Reports 58: 757–758 (1974).Google Scholar
  91. Evans, J.S.; Musser, E.A.; Mengel, C.D. et al.: Antitumor activity of 1 -β-D-arabinofuranosyl cytosine hydrochloride. Proceedings of the Society for Experimental Biology and Medicine 106: 350–353 (1961).PubMedGoogle Scholar
  92. Fenselau, C.: Review of the metabolism and mode of action of cyclophosphamide. Journal of the Association of Official Analytical Chemists 59: 1028–1036 (1976).Google Scholar
  93. Field, R.B.; Gang, M.; Kline, I. et al.: The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo. Journal of Pharmacology and Experimental Therapeutics 180: 475–483 (1972).PubMedGoogle Scholar
  94. Finn, C. and Sadee, W.: Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemotherapy Reports 59: 279–286 (1975).Google Scholar
  95. Frei, E.; Bickers, J.N.; Hewlett, J.S. et al.: Dose schedule and antitumor studies of arabinosylcytosine (NSC-63878). Cancer Research 29: 1325–1332 (1969).PubMedGoogle Scholar
  96. Gabbay, E.J.; Grier, D.; Fingerle, R.E. et al.: Interaction specificity of the anthracyclines with deoxyribonucleic acid. Biochemistry 15: 2062–2070 (1976).PubMedGoogle Scholar
  97. Ghione, M.: Development of adriamycin (NSC-123127). Cancer Chemotherapy Reports 6(3): 83–89 (1975).Google Scholar
  98. Goldman, I.D.; White, J.C. and Loftfield, S.: Mechanism of activation of methotrexate. III. Free intracellular methotrexate is required for maximal suppression of 14C-formate incorporation into nucleic acids and protein. Molecular Pharmacology 11: 287–297 (1975).PubMedGoogle Scholar
  99. Gonzalez-Vitale, J.C.; Hayes, D.M.; Cvitkovic, E. et al.: The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 39: 1362–1371 (1977).Google Scholar
  100. Goodman, M.F.; Lee, G.M. and Bachur, N.R.: Adriamycin interactions with T4 DNA polymerase. Journal of Biological Chemistry 252: 2670–2674 (1977).PubMedGoogle Scholar
  101. Gray, G.D.: The immunosuppressive activity of ara-C (cytarabine) and derivatives. Transplantation Proceedings 5: 1203–1209 (1973).PubMedGoogle Scholar
  102. Greco, F.A.; Brereton, H.D.; Kent, H. et al.: Adriamycin and enhanced radiation reaction in normal esophagus and skin. Annals of Internal Medicine 85: 294–298 (1976).PubMedGoogle Scholar
  103. Grindey, G. and Moran, R.: Effects of allopurinol on the therapeutic efficacy of methotrexate. Cancer Research 35: 1702–1705 (1975).PubMedGoogle Scholar
  104. Hahn, G.M. and Strande, D.P.: Cytotoxic effects of hyperthermia and adriamycin on Chinese hamster cells. Journal of the National Cancer Institute 57: 1063–1067 (1976).PubMedGoogle Scholar
  105. Hahn, G.M.; Braun, J. and Har-Kedar, I.: Thermochemotherapy: Synergism between hyperthermia (42–43 degrees) and adriamycin (or bleomycin) in mammalian cell inactivation. Proceedings of the National Academy of Sciences U.S.A 72: 937–945 (1975).Google Scholar
  106. Hahn, R.G.; Moertel, C.G.; Schutt, A.J. et al.: A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. Cancer 35: 1031–1035 (1975).PubMedGoogle Scholar
  107. Hanasono, G.K. and Fischer, L.J.: Plasma levels and urinary excretion of [14C] cyclophosphamide and its radioactive metabolites in rats pretreated with prednisolone. Biochemical Pharmacology 21: 272–276 (1972).PubMedGoogle Scholar
  108. Hande, K.R. and Chabner, B.A.: Deoxycytidine monophosphate kinase from human leukemic leukocytes. Proceedings of the American Association for Cancer Research 17: 67 (1976).Google Scholar
  109. Harbors, E.; Chaudhuri, N.K. and Heidelberger, C.: Studies of fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. Journal of Biological Chemistry 234: 1255–1262 (1959).Google Scholar
  110. Hardaker, W.T.; Stone, R.A. and McCoy, R.: Platinum nephrotoxicity. Cancer 34: 1030–1032 (1974).PubMedGoogle Scholar
  111. Harder, H.C.: Renaturation effects of cis and trans platinum II and IV compounds on calf thymus deoxyribonucleic acid. Chemical-Biological Interactions 10: 27–39 (1975).Google Scholar
  112. Harder, H.C. and Rosenberg, B.: Inhibitory effects of antitumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. International Journal of Cancer 6: 207–216 (1970).Google Scholar
  113. Harris, P.A. and Gross, J.F.: Preliminary pharmacokinetic model for adriamycin (NSC-123127). Cancer Chemotherapy Reports 59(1): 819–825 (1975).Google Scholar
  114. Haskell, C.M.; Eilber, F.R. and Morton, D.L.: Adriamycin (NSC-123127) by arterial infusion. Cancer Chemotherapy Reports 6(3): 187–189 (1975).Google Scholar
  115. Hayakawa, T.; Kanai, N.; Yamada, R. et al.: Effect of steroid hormone on activation of endoxan (cyclophosphamide). Biochemical Pharmacology 18: 129–135 (1969).PubMedGoogle Scholar
  116. Hayes, D.M.; Cvitkovic, E.; Golbey, R.B. et al.: High dose cis-platinum diamminedichloride. Cancer 39: 1372–1381 (1977).PubMedGoogle Scholar
  117. Heidelberger, C.: Fluorinated pyrimidines and their nucleosides; in Sartorelli and Johns (Eds) Handbook of Experimental Pharmacology, p. 193–231 (Springer-Verlag, New York 1974).Google Scholar
  118. Heidelberger, C.; Ghobar, A.; Baker, R.K. et al.: Studies on fluorinated pyrimidines. X. In vivo studies on tumor resistance. Cancer Research 20: 897–902 (1960).PubMedGoogle Scholar
  119. Heidelberger, C.; Griesbach, L.; Cruz, O. et al.: Fluorinated pyrimidines. VI. Effects of 5-fluorouridine and 5-fluoro-2′-deoxyuridine on transplanted tumors. Proceedings of the Society of Experimental Biology 97: 470–475 (1958).Google Scholar
  120. Heinen, E. and Bassleer, R.: Mode of action of cis-dichlorodiammine platinum (II) on mouse Ehrlich ascites tumour cells. Biochemical Pharmacology 25: 1871–1875 (1976).PubMedGoogle Scholar
  121. Higby, D.J.; Buchholtz, L.; Chary, K. et al.: Kinetics of cis-platinum with intensive diuresis. Proceedings of the American Association for Cancer Research 18: 110 (1977).Google Scholar
  122. Higby, D.J.; Wallace, H.J., Jr and Holland, J.F.: Cis-diamminedichloroplatinum (NSC-119875): A phase I study. Cancer Chemotherapy Reports 57: 459–463 (1973).Google Scholar
  123. Hill, D.L.; Laster, W.R. and Struck, R.F.: Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite. Cancer Research 32: 658–665 (1972).PubMedGoogle Scholar
  124. Ho, D.H.W. and Frei, E.: Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clinical Pharmacology and Therapeutics 12: 944–954 (1971).PubMedGoogle Scholar
  125. Hodes, M.E.; Rohn, R.J. and Bond, W.E.: Vincaleukoblastine. I. Preliminary Clinical Studies. Cancer Research 20: 1041–1049 (1960).PubMedGoogle Scholar
  126. Holoye, P.Y.; Broughton, A.; Strong, J.E. et al.: Bleomycin pharmacokinetics of continuous intravenous infusion. Proceedings of the American Association for Cancer Research 17: 70 (1977).Google Scholar
  127. Horacek, P. and Drobnik, J.: Interaction of cis-dichlorodiam-mineplatinum (II) with DNA. Biochima et Biophysica Acta 254: 341–347 (1971).Google Scholar
  128. Horton, J.; Olson, K.B.; Sullivan, J. et al.: 5-Fluorouracil in cancer: An improved regimen. Annals of Internal Medicine 73: 897–900 (1970).Google Scholar
  129. Howie, J.A. and Gale, G.R.: Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Bio. Pharmacol. 19: 2757–2762 (1970).Google Scholar
  130. Howie, J.A.; Thompson, H.S.; Stone, A.E. et al.: Cisdichlorodiammineplatinum [II]: Inhibition of nucleic acid synthesis in lymphocytes stimulated with phytohemagglutinin. Proceedings of the Society for Experimental Biology and Medicine 137: 820–826 (1971).Google Scholar
  131. Huffman, D.H.; Wan, S.H.; Azarnoff, D.L. and Hoogstraten, B.: Pharmacokinetics of methotrexate. Clinical Pharmacology and Therapeutics 14: 572–579 (1973).PubMedGoogle Scholar
  132. Hum, G.J. and Bateman, J.R.: 5-Day IV infusion with 5-fluorouracil (5-FU; NSC-19893) for gastroenteric carcinoma after failure on weekly 5-FU therapy. Cancer Chemotherapy Reports 59: 1177–1179 (1975).Google Scholar
  133. Ishida, R. and Takahashi, T.: Increased DNA chain breakage by combined action of bleomycin and superoxide radical. Biochemical and Biophysical Research Communications 66: 1432–1438 (1975).PubMedGoogle Scholar
  134. Israel, M.; Modest, B.J. and Frei, E.: N-trifluoroacetyl adriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Research 35: 1365–1368 (1975).PubMedGoogle Scholar
  135. Isralli, Z.H.; Vogler, W.; Mingioli, E. et al.: The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by constant infusion. Cancer Research 36: 1453–1461 (1976).Google Scholar
  136. Jacobs, E.M.; Reeves, W.J.; Wood, D.A. et al.: Treatment of cancer with weekly intravenous 5-fluorouracil. Cancer 27: 1302–1305 (1971).PubMedGoogle Scholar
  137. Jacobs, S.A.; Bleyer, W.A.; Chabner, B.A. et al.: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1: 465–466 (1975). Letter.PubMedGoogle Scholar
  138. Jacobs, S.A.; Stoller, R.G.; Chabner, B.A. et al.: 7-Hydroxy-methotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. Journal of Clinical Investigation 57: 534–538 (1976).PubMedGoogle Scholar
  139. Jacquez, J.A.: Permeability of Ehrlich cells to uracil, thymine and fluorouracil. Proceedings of the Society of Experimental Biology and Medicine 109: 132–135 (1962).Google Scholar
  140. Jaffe, N.; Frei, E.; Traggis, D. et al.: Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. New England Journal of Medicine 291: 994–997 (1974).PubMedGoogle Scholar
  141. Jao, J.Y.; Jusko, W.J. and Cohen, J.L.: Phenobarbitol effects on cyclophosphamide pharmacokinetics in man. Cancer Research 32: 2761–2764 (1972).PubMedGoogle Scholar
  142. Johnson, I.S.; Armstrong, J.C.; Gorman, M. et al.: The Vinca alkaloids: A new class of oncolytic agents. Cancer Research 23: 1390–1427 (1963).PubMedGoogle Scholar
  143. Johnson, I.S.; Wright, H.F.; Svoboda, G.H. et al.: Antitumor principles derived from Vinca rosea linn. I. Vincaleukoblastine and leurosine. Cancer Research 20: 1016–1022 (1960).PubMedGoogle Scholar
  144. Karon, M.; Freireich, E.J. and Frei, E.: A preliminary report on vincristine sulfate — A new active agent for the treatment of acute leukemia. Pediatrics 30: 791–796 (1962).Google Scholar
  145. Keller-Juslen, G.; Kuhn, M.; Von Wartburg, A. et al.: Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. Journal of Medicinal Chemistry 14: 936–940 (1971).PubMedGoogle Scholar
  146. Kent, R.J. and Heidelberger, C.: Fluorinated pyrimidines. XL. The reduction of 5-fluorouridine-5′-diphosphate by ribonucleotide reductase. Molecular Pharmacology 8: 465–475 (1972).PubMedGoogle Scholar
  147. Kessel, D.; Bruns, R. and Hall, T.C.: Determinants of responsiveness to 5-fluorouracil in transplantable murine leukemias. Molecular Pharmacology 7: 117–121 (1971).PubMedGoogle Scholar
  148. Kessel, D.; Hall, T.C. and Rosenthal, D.: Uptake and phosphorylation of cytosine arabinoside by normal and leukemic human blood cells in vitro. Cancer Research 29: 459–463 (1969).PubMedGoogle Scholar
  149. Kessel, D. and Wodinsky, I.: Thymidine kinase as a determinant of the response to 5-fluoro-2′-deoxyuridine in transplantable murine leukemias. Molecular Pharmacology 6: 251–254 (1970).PubMedGoogle Scholar
  150. Kikuchi, H. and Sato, S.: Binding of daunomycin to nonhistone proteins from rat liver. Biochimica et Biophysica Acta 434: 509–512 (1976).PubMedGoogle Scholar
  151. Kimelberg, H.K.; Biddlecombe, S.M. and Bourke, R.S.: Distribution and degradation of [3H] methotrexate after intravenous and cerebral intraventricular injection in primates. Cancer Research 37: 157–165 (1977).PubMedGoogle Scholar
  152. King, L. and Sullivan, M.: Colchicine-like effect of podophyllotoxin. Science 10: 244–245 (1946).Google Scholar
  153. Koch-Weser, J. and Sellers, E.M.: Drug therapy: binding of drugs to serum albumin. New England Journal of Medicine 294: 311–316, 526-531 (1976).PubMedGoogle Scholar
  154. Kociba, R.J. and Sleight, S.D.: Acute toxicologic and pathologic effects of cis-diamminedichloroplatinum (NSC-119875) in the male rat. Cancer Chemotherapy Reports 55: 1–8 (1971).Google Scholar
  155. Koenig, H. and Patel, A.: Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Archives of Neurology 23: 155–160 (1970).PubMedGoogle Scholar
  156. Kraybill, W.G.; Harrison, M.; Sasaki, T. et al.: Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surgery, Gynecology, and Obstetrics 144: 335–338 (1977).Google Scholar
  157. Kreis, W.; Woodcock, T.; Tan, C. et al.: Physiological distribution of tetrahydrouridine and its effects upon the deamination of arabinosylcytosine in humans. Proceedings of the American Association for Cancer Research 18: 226 (1977).Google Scholar
  158. Kremer, W.B.: Cytarabine. Annals of Internal Medicine 82: 684–688 (1975).PubMedGoogle Scholar
  159. Krishan, A. and Frei, E.: Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Research 36: 143–150 (1976).PubMedGoogle Scholar
  160. Krishan, A.; Paika, K. and Frei, E.: Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts. Journal of Cell Biology 66: 521–530 (1975).PubMedGoogle Scholar
  161. Kristensen, L.O.; Weismann, K. and Hutters, L.: Renal function and the rate of disappearance of methotrexate from serum. Europ. J. Clin. Pharmacol. 8: 439–444 (1975).Google Scholar
  162. Kupchan, S.M.; Komoda, Y.; Court, W.A. et al.: Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. Journal of the American Chemical Society 94: 1354–1356 (1972).PubMedGoogle Scholar
  163. Kushner, J.P.; Hansen, V.L. and Hammar, S.P.: Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin D and mithramycin. Cancer 36: 1577–1584 (1975).PubMedGoogle Scholar
  164. Lange, R.C.; Spencer, R.P. and Harder, H.C.: Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum (II). Journal of Nuclear Medicine 13: 328–330 (1972).PubMedGoogle Scholar
  165. Lange, R.C.; Spencer, R.P. and Harder, H.C.: The antitumor agent cis-PT(NH3)2Cl2: Distribution studies and dose calculations for 193mPt and l95mpt. Journal of Nuclear Medicine 14: 191–195 (1973).PubMedGoogle Scholar
  166. Lee, T. and Momparler, R.L.: Kinetic studies with 5-azacytidine 5′-triphosphate and DNA dependent RNA polymerase. Biochemical Pharmacology 26: 403–406 (1977).PubMedGoogle Scholar
  167. Lee, Y.C. and Byfield, J.E.: Induction of DNA degradation in vivo by adriamycin. Journal of the National Cancer Institute 57: 221–224 (1976).PubMedGoogle Scholar
  168. Lefrak, E.A.; Pitha, J.; Rosenheim, S. et al.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302–314 (1973).PubMedGoogle Scholar
  169. Lenaz, L. and Page, J.A.: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treatment Reviews 3: 111–120 (1976).PubMedGoogle Scholar
  170. Leonard, B.J. Eccleston, E.; Jones, D. et al.: Antileukaemic and nephrotoxic properties of platinum compounds. Nature 234: 43–45 (1971).PubMedGoogle Scholar
  171. Levitan, I.B. and Webb, T.E.: Effects of 5-azacytidine on polyribosomes and on the control of tyrosine transaminase activity in rat liver. Biochimica et Biophysica Acta 182: 491–500 (1969).PubMedGoogle Scholar
  172. Levitt, M.; Mosher, M.B.; DeConti, R.C. et al.: Improved therapeutic index of methotrexate with ‘leucovorin rescue’. Cancer Research 33: 1729–1734 (1973).PubMedGoogle Scholar
  173. Levy, R.; Hurwitz, E.; Maron, R. et al.: The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies. Cancer Research 35: 1182–1186 (1975).PubMedGoogle Scholar
  174. Li, L.H.; Olin, E.J.; Buskirk, H.H. et al.: Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Research 30: 2760–2769 (1970a).PubMedGoogle Scholar
  175. Li, L.H.; Olin, E.J.; Fraser, T.J. et al.: Phase specificity of 5-azacytidine against mammalian cells in tissue culture. Cancer Research 30: 2770–2775 (1970b).PubMedGoogle Scholar
  176. Liegler, D.G.; Henderson, E.S.; Hahn, M.A. et al.: The effect of organic acids on renal clearance of methotrexate in man. Clinical Pharmacology and Therapeutics 10: 849–857 (1969).PubMedGoogle Scholar
  177. Litterst, C.L.; Gram, T.E.; Dedrick, R.L. et al.: Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum (II) (NSC-119875) to dogs. Cancer Research 36: 2340–2344 (1976).PubMedGoogle Scholar
  178. Livingston, R.B. and Carter, S.K.::Single agents in cancer chemotherapy. Plenum Press, New York (1970).Google Scholar
  179. Loike, J.D. and Horwitz, S.B.: Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 15: 5435–5442 (1976a).PubMedGoogle Scholar
  180. Loike, J.D. and Horwitz, S.B.: Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15: 5443–5448 (1976b).PubMedGoogle Scholar
  181. Lown, J.W.; Sim, S. and Majumdar, K.C.: Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents. Biochemical and Biophysical Research Communications 76: 705–710 (1977).PubMedGoogle Scholar
  182. Mandelbaum-Shavit, F.; Wolpert-DeFilippes, M.K. and Johns, D.G.: Binding of Maytansine to rat brain tubulin. Biochemical and Biophysical Research Communications 72: 47–54 (1976).PubMedGoogle Scholar
  183. Marquardt, H.; Philips, F.S. and Sterberg, S.S.: Tumorigenicity in vivo and induction of malignant transformation and mutogenesis in cell cultures by adriamycin and daunomycin. Cancer Research 36: 2065–2069 (1976).PubMedGoogle Scholar
  184. McCredie, K.B.; Bodey, G.P.; Burgess, M.A. et al.: Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemotherapy Reports 57: 319–323 (1973).Google Scholar
  185. Mellett, L.B.: Chemistry and metabolism of cyclophosphamide; in Vancil (Ed) Immunosuppressive Properties of Cyclophosphamide, p.6–34 (Meade Johnson, Evansville, Ind. 1971).Google Scholar
  186. Merski, J.A.; Daskal, I. and Busch, H.: Effects of adriamycin on ultrastructure of nucleoli in the heart and liver cells of the rat. Cancer Research 36: 1580–1584 (1976).PubMedGoogle Scholar
  187. Minow, R.A.; Benjamin, R.S.; Lee, E.T. et al.: Adriamycin cardiomyopathy risk factors. Cancer 39: 1397–1402 (1977).PubMedGoogle Scholar
  188. Miyak, M.; Ono, T.; Hori, S. et al.: Binding of bleomycin to DNA in bleomycin-sensitive and -resistant rat ascites hepatoma cells. Cancer Research 35: 2015–2019 (1975).Google Scholar
  189. Moertel, C.G.: Clinical management of advanced gastrointestinal cancer. Cancer 36: 675–682 (1975).PubMedGoogle Scholar
  190. Moertel, C.G.; Reitemeier, R.J. and Hahn, R.G.: A controlled comparison of 5-fluoro-2′-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion. Cancer Research 27: 549–552 (1967).PubMedGoogle Scholar
  191. Momparler, R.L.: Kinetic and template studies with 1-β-D-arabinofuranosylcytosine 5′-triphosphate and mammalian deoxyribonucleic acid polymerase. Molecular Pharmacology 8: 362–370 (1972).PubMedGoogle Scholar
  192. Momparler, R.L.: A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Research 34: 1775–1787 (1974).PubMedGoogle Scholar
  193. Momparler, R.L.; Chu, M.Y. and Fischer, G.A.: Studies on a new mechanism of resistance of L1578Y murine leukemia cells to cytosine arabinoside. Biochimica et Biophysica Acta 161: 481–493 (1968).PubMedGoogle Scholar
  194. Momparler, R.L.; Karon, M.; Siegel, S.E. et al.: Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Research 36: 2891–2895 (1976).PubMedGoogle Scholar
  195. Mosher, M.B.; DeConti, R.C. and Bertino, J.R.: Bleomycin therapy in advanced Hodgkn’s disease and epidermoid cancers. Cancer 30: 56–60 (1972).PubMedGoogle Scholar
  196. Muggia, F.M.; Selawry, O.S. and Hansen, H.H.: Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4′demethyl-9-(4,6-0-2-thenylidene-β-D-glucopyranoside) (NSC-122819). Cancer Chemotherapy Reports 55: 575–581 (1971).Google Scholar
  197. Mukherjee, K.L.; Curreri, A.R.; Javid, M. et al.: Studies on fluorinated pyrimidines. XVII. Tissue distribution of 5-fluorouracil-2-C14 and 5-fluoro-2′-deoxyuridine in cancer patients. Cancer Research 23: 67–77 (1963).Google Scholar
  198. Mukherjee, K.L. and Heidelberger, C.: Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. Journal of Biological Chemistry 235: 433–437 (1960).PubMedGoogle Scholar
  199. Mulder, J.H. and Harrap, K.R.: Cytosine arabinoside uptake by tumor cells in vitro. European Journal of Cancer 11: 373–379 (1975).PubMedGoogle Scholar
  200. Munchausen, L.L.: The chemical and biological effects of cisdichlorodiammineplatinum (II), an antitumor agent, on DNA. Proceedings of the National Academy of Sciences U.S.A. 71: 4519–4522 (1974).Google Scholar
  201. Myers, C.E.; Lippman, M.E.; Eliot, H.M. et al.: Competitive protein binding assay for methotrexate. Proceedings of the National Academy of Sciences U.S.A. 72: 3683–3686 (1975).Google Scholar
  202. Myers, C.E.; Young, R.C. and Chabner, B.A.: Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. Journal of Clinical Investigation 56: 1231–1238 (1975).PubMedGoogle Scholar
  203. Nagai, K.; Suzuki, H.; Tanaka, N. et al.: Decrease of melting temperature and single strand scission of DNA by bleomycin in the presence of hydrogen peroxide. Journal of Antibiotics (Tokyo) 22: 624–628 (1969).Google Scholar
  204. Nahas, A.; Savlov, E.D. and Hall, T.C.: Phosphoribosyl transferase in colon tumor and normal mucosa as an aid in adjuvant chemotherapy with 5-fluorouracil (NSC-19893). Cancer Chemotherapy Reports 58: 909–912 (1974).Google Scholar
  205. Nelson, R.L.; Root, M.A.; Dyke, R.W. et al.: Pharmacokinetics of desacetyl vinblastine amide (Vindesine) in man. Proceedings of the American Association for Cancer Research 17: 30 (1976).Google Scholar
  206. Newsome, Y.L. and Singh, D.N.: Cytologic effects of adriamycin on human peripheral lymphocytes. Acta Cytologica 21: 137–140 (1977).PubMedGoogle Scholar
  207. Nirenberg, A.; Mosende, C.; Mehta, B. et al.: High dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treatment Reports 61: 779–783 (1977).PubMedGoogle Scholar
  208. Nissen, N.I.; Dombernowsky, P.; Hansen, H.H. et al.: Phase I clinical trial of an oral solution of VP-16-213. Cancer Treatment Reports 60: 943–945 (1976).PubMedGoogle Scholar
  209. Nissen, N.I.; Larsen, V.; Pedersen, H. et al.: Phase I clinical trial of a new antitumor agent, 4′-demethyl epipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemotherapy Reports 56: 769–777 (1972).Google Scholar
  210. Ohnuma, T.; Holland, J.F. and Chen, J.H.: Pharmacological and therapeutic efficacy of daunomycin-DNA complex in mice. Cancer Research 35: 1767–1772 (1975).PubMedGoogle Scholar
  211. Overgaard, J.: Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo. Cancer Research 36: 3077–3081 (1976).PubMedGoogle Scholar
  212. Owellen, R.J. and Hartke, C.A.: The pharmacokinetics of 4-acetyltritium vinblastine in two patients. Cancer Research 35: 975–980 (1975).PubMedGoogle Scholar
  213. Owellen, R.J.; Hartke, C.A. and Hains, F.O.: Pharmacokinetics and metabolism of vinblastine in humans. Cancer Research 37: 2597–2602 (1977a).PubMedGoogle Scholar
  214. Owellen, R.J.; Owens, A.H. and Donigan, D.W.: The binding of vincristine, vinblastine, and colchicine to tubulin. Biochemical and Biophysical Research Communications 47: 685–691 (1972).PubMedGoogle Scholar
  215. Owellen, R.J.; Root, M.A. and Hains, F.O.: Pharmacokinetics of vindesine and vincristine in humans. Cancer Research 37: 2603–2607 (1977b).PubMedGoogle Scholar
  216. Pascoe, J.M. and Roberts, J.J.: Interactions between mammalian cell DNA and inorganic platinum compounds. Biochemical Pharmacology 23: 1345–1357 (1974).PubMedGoogle Scholar
  217. Philips, F.S.; Gilladoga, A.; Marquardt, H. et al.: Some observations on the toxicity of adriamycin (NSC-123127). Cancer Chemotherapy Reports 6: 177–181 (1975).Google Scholar
  218. Piel, I.J.; Meyer, D.; Perlia, C.P. et al.: Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemotherapy Reports 58: 871–875 (1974).Google Scholar
  219. Pinedo, H.M. and Chabner, B.A.: The role of drug concentration, duration of exposure, and endogenous metabolites in determining MTX cytoxicity. Cancer Treatment Reports 61: 709–715 (1977).PubMedGoogle Scholar
  220. Pinedo, H.M.; Zaharko, D.S.; Bull, J.M. et al.: The reversal of methotrexate cytotoxicity of mouse bone marrow cells by leucovorin and nucleosides. Cancer Research 36: 4418–4424 (1976).PubMedGoogle Scholar
  221. Presant, C.A.; Klahr, C. and Santala, R.: Amphotericin B induction of sensitivity to adriamycin, l,3-bis(2-chloroethyl)-l-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia. Annals of Internal Medicine 86: 47–51 (1977).PubMedGoogle Scholar
  222. Primack, A.: Amelioration of cyclophosphamide-induced cystitis. Journal of the National Cancer Institute 47: 223–227 (1971).PubMedGoogle Scholar
  223. Quagliana, J.M.; O’Bryan, R.M.; Baker, L. et al.: Phase II study of 5-azacytidine in solid tumors. Cancer Chemotherapy Reports 61: 51–58 (1977).Google Scholar
  224. Ramos, A.; Meyer, R.A.; Korfhagen, J. et al.: Echocardiographic evaluation of adriamycin cardiotoxicity in children. Cancer Treatment Reports 60: 1281–1284 (1976).PubMedGoogle Scholar
  225. Rashbaum, S.A. and Cozzarelli, N.R.: Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature 264: 679–680 (1976).PubMedGoogle Scholar
  226. Raso, V. and Schreiber, R.: A rapid and specific radioimmunoassay for methotrexate. Cancer Research 35: 1407–1410 (1975).PubMedGoogle Scholar
  227. Reich, S.D. and Bachur, N.R.: Alterations in adriamycin efficacy by phenobarbital. Cancer Research 36: 3803–3806 (1976).PubMedGoogle Scholar
  228. Reilly, M.J.: Drug information digest: Methotrexate USP (amethopterin) and methotrexate sodium. American Journal of Hospital Pharmacy 30: 542–548 (1973).Google Scholar
  229. Reimer, R.R.; Hoover, R.; Fraumeni, J.F. et al.: Acute leukemia after alkylating-agent therapy of ovarian cancer. New England Journal of Medicine 297: 177–181 (1977).PubMedGoogle Scholar
  230. Reitemeier, R.J.; Moertel, C.G. and Hahn, R.G.: Comparison of 5-fluorouracil (NSC-19893) and 2′-deoxy-5-fluorouridine (NSC-27640) in the treatment of patients with advanced adenocarcinoma of colon or rectum. Cancer Chemotherapy Reports 44: 39–43 (1965).Google Scholar
  231. Remillard, S.; Rebhun, L.I.; Howie, G.A. et al.: Antitumor activity of the potent tumor inhibitor Maytansine. Science 189: 1002–1005 (1975).PubMedGoogle Scholar
  232. Reslova, S.: The induction of lysogenic strains of Escherichia coli by cis-dichlorodiammine-platinum (II). Chemico-Biological Interactions 4: 66–70 (1971).PubMedGoogle Scholar
  233. Reyes, P.: The synthesis of 5-fluorouridine-5′-phosphate by a pyrimidine phosphoribosyl transferase of mammalian origin. I. Some properties of the enzyme from P1534J mouse leukemic cells. Biochemistry 8: 2057–2062 (1969).PubMedGoogle Scholar
  234. Reyes, P. and Heidelberger, C.: Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism of action and inhibition by fluorinated nucleotides. Molecular Pharmacology 1: 14–30 (1965).PubMedGoogle Scholar
  235. Richman, S.D.; Levenson, S.M.; Bunn, P.A. et al.: 67Ga-accumulation in pulmonary lesions associated with bleomycin toxicity. Cancer 36: 1966–1972 (1975).PubMedGoogle Scholar
  236. Rinehart, J.J.; Lewis, R.P. and Balcerzak, S.P.: Adriamycin cardiotoxicity in man. Ann. Intern. Med. 81: 475–478 (1974).PubMedGoogle Scholar
  237. Roberts, D.W. and Hall, T.C.: Triamterene-induced elevation of dihydrofolate reductase activity in human leukocytes. Biochemical Pharmacology 17: 484–487 (1968).Google Scholar
  238. Roberts, J.J. and Pascoe, J.M.: Cross-linking of complementary strands of DNA in mammalian cells by antitimour platinum compounds. Nature 235: 282–284 (1972).PubMedGoogle Scholar
  239. Rosenberg, B.: Possible mechanism for the antitumor activity of platinum coordination complexes. Cancer Chemotherapy Reports 59: 589–598 (1975).Google Scholar
  240. Rosenberg, B.; Van Camp, L. and Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699 (1965).PubMedGoogle Scholar
  241. Rosenberg, B.; Van Camp, L.; Troska, J.E. et al.: Platinum compounds: a new class of potent antitumor agents. Nature 222: 385–386 (1969).PubMedGoogle Scholar
  242. Rosenthal, S.M. and Kaufman, S.: Vincristine neurotoxicity. Annals of Internal Medicine 80: 733–737 (1974).PubMedGoogle Scholar
  243. Rozencweig, M.; Von Hoff, D.D.; Henney, J.E. et al.: VM-26 and VP-16-213: A comparative analysis. Cancer 40: 334–342 (1977a).PubMedGoogle Scholar
  244. Rozencweig, M.; Von Hoff, D.D.; Slavik, M. et al.: Cis-diamminedichloroplatinum (II). Annals of Internal Medicine 86: 803–812 (1977b).PubMedGoogle Scholar
  245. Sadee, W. and Wong, C.G.: Pharmacokinetics of 5-fluorouracil: Inter-relationship with biochemical kinetics in monitoring therapy. Clinical Pharmacokinetics 2: 437–450 (1977).PubMedGoogle Scholar
  246. Samuels, M.L.; Johnson, D.E. and Holoye, P.Y.: Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) stage III testicular neoplasia. Cancer Chemotherapy Reports 59: 563–701 (1975).Google Scholar
  247. Santi, D.V.; McHenry, C.S. and Sommer, H.: Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13: 471–481 (1974).PubMedGoogle Scholar
  248. Schaeppi, U.; Heyman, I.A.; Fleischman, R.W. et al.: Cisdichlorodiammineplatinum (II) (NSC-119875): Preclinical toxicologic evaluation of intravenous injection in dogs, monkeys and mice. Toxicology and Applied Pharmacology 25: 230–241 (1973).PubMedGoogle Scholar
  249. Seifert, P.; Baker, L.H.; Reed, M.L. et al.: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36: 123–128 (1975).PubMedGoogle Scholar
  250. Shapiro, W.R., Yound, D.F. and Mehta, B.M.: Methotrexate: Distribution in cerebrospinal fluid and intravenous, ventricular, and lumbar injections. New England Journal of Medicine 293: 161–166 (1975).PubMedGoogle Scholar
  251. Shindler, B.I.; Baig, M. and Colsky, J.: Phase I study of 5-azacytidine. Journal of Clinical Pharmacology 16: 205–212 (1976).Google Scholar
  252. Shooter, K.V.; Howse, R.; Merrifield, R.K. et al.: The interaction of platinum II compounds with bacteriophages T7 and R17. Chemico-Biological Interactions 5: 289–307 (1972).PubMedGoogle Scholar
  253. Sieber, S.M. and Adamson, R.H.: Toxicity of antineoplastic agents in man. Chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential; in Klein; Weinhouse; Haddow (Eds) Advances in Cancer Research, p.57–155 (Academic Press, New York 1975).Google Scholar
  254. Skold, O.: Enzymatic ribosidation and ribotidation of 5-fluorouracil by extracts of the Ehrlich ascites tumor. Biochimica et Biophysica Acta 29: 651 (1958).PubMedGoogle Scholar
  255. Skold, O.; Magnusson, P.H. and Revesz, L.: Studies on resistance against 5-fluorouracil. III. Selective value of resistant, uridine kinase-deficient tumor cells. Cancer Research 22: 1226–1229 (1962).PubMedGoogle Scholar
  256. Sladek, N.E.: Therapeutic efficacy of cylophosphamide as a function of its metabolism. Cancer Research 32: 535–542 (1972).PubMedGoogle Scholar
  257. Smart, C.R.; Townsend, L.B.; Rusho, W.J. et al.: Phase I study of ftorafur, an analog of 5-fluorouracil. Cancer 36: 103–106 (1975).PubMedGoogle Scholar
  258. Smith, B.J. and Kundi, D.: Digoxin does not prevent daunorubicin or adriamycin from binding to rat heart muscle. British Journal of Cancer 33: 232–233 (1976).PubMedGoogle Scholar
  259. Smith, P.H.S. and Taylor, D.M.: Distribution and retention of the antitumor agent ,95mPt-cis-dichlorodiammine platinum (II) in man. Journal of Nuclear Medicine 15; 349–351 (1974).PubMedGoogle Scholar
  260. Smyth, J.F.; Robbins, A.B. and Leese, CL.: The metabolism of cytosine arabinoside as a predictive test for clinical response to the drugs in acute myeloid leukemia. European Journal of Cancer 12: 567–573 (1976).PubMedGoogle Scholar
  261. Sostman, H.D.; Matthay, R.A.; Putnam, C.E. et al.: Methotrexate-induced pneumonitis. Medicine 55: 371–388 (1976).PubMedGoogle Scholar
  262. Stadnicki, S.W.; Fleischman, R.W.; Schaeppi, U. et al.: Cisdichlorodiammineplatinum (II) (NSC-119875): Hearing loss and other toxic effects in rhesus monkeys. Cancer Chemotherapy Reports 59: 467–480 (1975).Google Scholar
  263. Stahelin, H.: 4′Demethyl-epipodophyllotoxin thenylidene glucoside (VM26), a podophyllin compound with a new mechanism of action. European Journal of Cancer 6: 303–311 (1970).PubMedGoogle Scholar
  264. Stahelin, H.: Activity of a new glycosidic lignan derivative (VP-16-213) related to podophyllotoxin in experimental tumors. European Journal of Cancer 9: 212–221 (1973).Google Scholar
  265. Staquet, M.; Rozencweig, M.; Duarte-Karem, M. et al.: Pharmacokinetics of adriamycin and adriamycin-DNA complex in L1210 mice and men. European Journal of Cancer 13: 433–435 (1977).PubMedGoogle Scholar
  266. Steuart, C.D. and Burke, P.J.: Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nature [New Biology] 233: 109–110 (1971).Google Scholar
  267. Stevens, D.A.; Jordan, G.W.; Waddell, T.F. et al.: Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. New England Journal of Medicine 289: 873–878 (1973).PubMedGoogle Scholar
  268. Stolinsky, D.C.; Pugh, R.P. and Bateman, J.R.: 5-Fluorouracil (NSC-19893) therapy for pancreatic carcinoma: Comparison of oral and intravenous routes. Cancer Chemotherapy Reports 59: 1031–1033 (1975).Google Scholar
  269. Stoller, R.G.; Coleman, C.N.; Chang, P. et al.: Biochemical pharmacology of cytidine analog metabolism in human leukemic cells; in Clemmesen and Yohn (Eds) Bibliotheca Haematologica, p.531–533 (Basel, Karger 1976).Google Scholar
  270. Stoller, R.G.; Hande, K.R.; Jacobs, S.A. et al.: Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine 297: 630–634 (1977).PubMedGoogle Scholar
  271. Stoller, R.G.; Jacobs, S.A.; Drake, J.C. et al.: Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemotherapy Reports 6: 19–24 (1975).Google Scholar
  272. Takanashi, S. and Bachur, N.R.: Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metabolism and Disposition 4: 79–87 (1976).PubMedGoogle Scholar
  273. Talley, R.W.; (O’Bryan, R.M.; Gutterman, J.U. et al.: Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)-phase I clinical study. Cancer Chemotherapy Reports 57: 465–471 (1973).Google Scholar
  274. Tanlon, R.N.; Bunnell, I.L. and Cooper, R.G.: The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil. Surgery 73: 118–121 (1973).Google Scholar
  275. Tattersall, M.H.; Ganeshaguru, K. and Hoffbrand, A.V.: Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. British Journal of Haematology 27: 39–46 (1974).PubMedGoogle Scholar
  276. Thomson, A.J.; Williams, R.J.P. and Reslova, S.: The chemistry of complexes related to cis-Pt (NH3)2C12. An antitumor drug. Structure and Bonding 11: 1–46 (1972).Google Scholar
  277. Thomson, A.J.: The interactions of platinum compounds with biological molecules. Recent Results in Cancer Research 48: 38–62 (1974).Google Scholar
  278. Thompson, H.S. and Gale, G.R.: Cis-dichlorodiammineplatinum (II): Hematopoietic effects in rats. Toxicology and Applied Pharmacology 19: 602–609 (1971).PubMedGoogle Scholar
  279. Troetel, W.M.; Weiss, A.J.; Stambaugh, J.E. et al.: Absorption, distribution, and excretion of 5-azacytidine (NSC-102816) in man. Cancer Chemotherapy Reports 56: 405–411 (1972).Google Scholar
  280. Trouet, A.; Deprez De Campaneere, D. and De Duve, C.: Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature [New Biology] 239: 110–112 (1972).Google Scholar
  281. Umezawa, H.: Chemistry and mechanism of action of bleomycin. Federation Proceedings 33: 2296–2302 (1974).PubMedGoogle Scholar
  282. Umezawa, H.; Hori, S.; Sawa, T. et al.: A bleomycin-inactivating enzyme in mouse liver. Journal of Antibiotics 27: 419–424 (1974).PubMedGoogle Scholar
  283. Valdivieso, M.; Bodey, G.P.; Gottlieb, J.A. et al.: Clinical evaluation of ftorafur (pyrimidine-deoxyribose N1-2′-furanidyl-5-fluorouracil). Cancer Research 36: 1821–1824 (1976).PubMedGoogle Scholar
  284. Van den Berg, H.W. and Roberts, J.J.: Investigations into the mechanism of action of antitumor platinum compounds: Time- and dose-dependent changes in the alkaline sucrose gradient sedimentation profiles of DNA from hamster cells treated with cis-platinum (II) diamminedichloride. Chemico-Biological Interactions 11: 493–499 (1975).PubMedGoogle Scholar
  285. Van den Berg, H.W. and Roberts, J.J.: Inhibition by caffeine of post-replication repair in Chinese hamster cells treated with cis-platinum (II) diamminedichloride: The extent of platinum binding to template DNA in relation to the size of low molecular weight nascent DNA. Chemico-Biological Interactions 12: 375–390 (1976).Google Scholar
  286. Vesely, J.; Cihak, A. and Sorm, F.: Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-azacytidine and 5-ara-2′-deoxycytidine. Cancer Research 30: 2180–2186 (1970).PubMedGoogle Scholar
  287. Vogler, W.R.; Miller, D.S. and Keller, J.W.: 5-Azacytidine: A new drug for the treatment of myeloblasts leukemia. Blood 48: 331–337 (1976).PubMedGoogle Scholar
  288. Von Hoff, D.D.; Penta, J.S.; Helman, L.J. et al.: The incidence of drug related deaths secondary to high dose methotrexate and citrovorum administration. Cancer Treatment Reports 61: 745–748 (1977a).Google Scholar
  289. Von Hoff, D.D.; Rozencweig, M.; Layard, M. et al.: Daunomycin-induced cardiotoxicity in children and adults. American Journal of Medicine 62: 200–208 (1977b).Google Scholar
  290. Von Hoff, D.D.; Slavik, M. and Muggia, F.M.: 5-Azacytidine: A new anticancer drug with effectiveness in acute myelogenous leukemia. Annals of Internal Medicine 85: 237–245 (1976a).Google Scholar
  291. Von Hoff, D.D.; Slavik, M. and Muggia, F.M.: Allergic reactions to cis-platinum. Lancet 1: 90 (1976b).Google Scholar
  292. Wan, S.H.; Huffman, D.H.; Azarnoff, D.L.; Stephens, R. and Hoogstraten, B.: Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Research 34: 3487–3491 (1974).PubMedGoogle Scholar
  293. Ward, J.M.; Arabin, M.E.; Berlin, E. et al.: Prevention of renal failure in rats receiving cisdiamminedichloroplatinum (II) by administration of furosemide. Cancer Research 37: 1238–1240 (1977).PubMedGoogle Scholar
  294. Ward, J.M. and Fauvie, K.A.: The nephrotoxic effects of cis-diamminedichloroplatinum (II) (NSC-1 19875) in male F344 rats. Toxicology and Applied Pharmacology 38: 535–547 (1976).PubMedGoogle Scholar
  295. Warren, R.D.; Nichols, A.P. and Bender, R.A.: The effect of vincristine on methotrexate uptake and inhibition of DNA synthesis by human lymphoblastoid cells. Cancer Research. 37: 2993–2997 (1977).PubMedGoogle Scholar
  296. Weiss, A.J.; Metter, G.E., Fletcher, W.S. et al.: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treatment Reports 60: 813–822 (1976).PubMedGoogle Scholar
  297. Weiss, H.D.; Walker, M.D. and Wiernik, P.H.: Neurotoxicity of commonly used antineoplastic agents. New England Journal of Medicine 291: 75–81, 127–133 (1974).PubMedGoogle Scholar
  298. Wilson, D.W.; Guer, D.; Reimer, R. et al.: Structure-activity relationship of daunorubicin and its peptide derivatives. Journal of Medicinal Chemistry 19: 381–384 (1976).PubMedGoogle Scholar
  299. Wolpert-DeFilippes, M.K.; Adamson, R.H.; Cysyk, R.L. et al.: Initial studies on the cytotoxic action of Maytansine, a novel ansa macrolide. Biochemical Pharmacology 24: 751–754 (1975a).PubMedGoogle Scholar
  300. Wolpert-DeFilippes, M.K.; Bono, V.H.; Dion, R.L. et al.: Initial studies on Maytansine-induced metaphase arrest in L1210 murine leukemia cells. Biochemical Pharmacology 24: 1735–1738 (1975b).PubMedGoogle Scholar
  301. Woodman, R.J.; Cysyk, R.L.; Kline, I. et al.: Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-59 (NSC-129943). Cancer Chemotherapy Reports 59: 689–695 (1975).Google Scholar
  302. Young, R.C.: Chemotherapy of ovarian cancer: Past and present. Seminars in Oncology 2: 267–276 (1975).PubMedGoogle Scholar
  303. Young, R.C.; Rosenoff, S.A.; Myers, C.E. et al.: Alterations in DNA synthesis induced by chemotherapeutic agents in vivo: Potential applications to clinical treatment schedules; in Growth Kinetics and Biochemical Regulation of Normal and Malignant Cells, University of Texas System Cancer Center, MD Anderson Hospital and Tumor Institute at Houston, (Williams and Wilkins, Baltimore 1976).Google Scholar
  304. Zager, R.F.; Frisby, S.A. and Oliverio, V.T.: The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Research 33: 1670–1676 (1973).PubMedGoogle Scholar
  305. Zaharko, D.S.; Bruchner, H. and Oliverio, V.T.: Antibiotics alter methotrexate metabolism and excretion. Science 166: 887–888 (1969).PubMedGoogle Scholar
  306. Zaharko, D.S.; Fung, W-P. and Yang, K-H.: Relative biochemical aspects of low and high doses of methotrexate in mice. Cancer Research 37: 1602–1607 (1977).PubMedGoogle Scholar
  307. Zak, M.; Drobnik, J. and Rezny, Z.: The effect of cisdichlorodiammineplatinum (II) of cytological and morphological changes in bone marrow of mice (long-term observations). Neoplasma 19: 305–310 (1972a).PubMedGoogle Scholar
  308. Zak, M.; Drobnik, J. and Rezny, Z.: The effect of cis-platinum (II) diamminodichloride on bone marrow. Cancer Research 32: 595–599 (1972b).PubMedGoogle Scholar
  309. Zunino, F.; Gambetta, R.; DiMarco, A. et al.: Interaction of daunomycin and its derivatives with DNA. Biochimica et Biophysica Acta 277: 489–498 (1972).PubMedGoogle Scholar

Copyright information

© ADIS Press 1978

Authors and Affiliations

  • Richard A. Bender
    • 1
  • Leonard A. Zwelling
    • 1
  • James H. Doroshow
    • 1
  • Gershon Y. Locker
    • 1
  • Kenneth R. Hande
    • 1
  • Donald S. Murinson
    • 1
  • Michael Cohen
    • 1
  • Charles E. Myers
    • 1
  • Bruce A. Chabner
    • 1
  1. 1.Medicine Branch and Clinical Pharmacology BranchNational Cancer InstituteBethesdaUSA

Personalised recommendations